3 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
Follow RAF Mutation: new trials by email Literature Review of RAF Mutation trials Research Report on RAF Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway DCC-3084 - Advanced Solid Tumor, RAF Mutation | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 29 | 2024-05-14 | 2026-03-05 |
| Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. ABM-168 - Advanced Solid Tumor, RAS Mutation | Phase 1 | Terminated | ABM Therapeutics Corporation | 12 | 2023-03-30 | 2024-12-06 |
| Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors Tovorafenib, Tovorafenib Drug: Pimasertib - Melanoma, Solid Tumor | Phase 1 | Terminated | Day One Biopharmaceuticals, Inc. | 44 | 2022-05-02 | 2025-08-14 |
Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Pancreatic Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Glioblastoma (1) · Lung Neoplasms (1)
Lung Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Nevi and Melanomas (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Skin Diseases (3) · Skin Neoplasms (3) · Skin and Connective Tissue Diseases (3) · Thoracic Neoplasms (3)
tovorafenib (1)
ABM Therapeutics Corporation (1) · Day One Biopharmaceuticals, Inc. (1) · Deciphera Pharmaceuticals, LLC (1)
United States (3) · Canada (1)